In 2020, the market size of antitumor drugs will reach 150 billion US dollars

[pharmaceutical network market analysis] cancer is one of the major medical problems that human beings need to overcome In recent years, the incidence rate of cancer has been increasing and the demand for medication has been increasing due to various objective factors such as the increasing living environment and the pressure of survival In this context, the world anti-tumor drug market began to grow rapidly In just five years, the global anti-tumor drug market sales have doubled, and the market growth has far exceeded other drugs Statistics show that in 2016, the global tumor drug market reached US $114.5 billion, accounting for 10.3% of the global drug sales; it is estimated that in 2020, the global tumor drug market will exceed US $150 billion, and the tumor prescription drug sales will exceed US $110 billion In fact, in addition to the growing global anti-tumor drug market, in China's hospital drug market, the sales scale of anti-tumor drugs has been growing steadily in recent years, especially in 2003-2005, the compound growth rate reached 24.53% In 2006, under the influence of the policy environment such as the national governance of commercial bribery in the purchase and sale of medicine, the growth rate of the market scale of anti-tumor drugs slowed down, only increased by 11.10% From 2007 to 2010, the sales scale continued to grow rapidly, reaching 58.74 billion yuan in 2011, up 17.13% year on year Among them, it is worth noting that targeting small molecule drugs are occupying more and more anti-tumor drug market It can be seen from the global types of anti-tumor drugs that during 1997-2017, 141 anti-tumor drugs (excluding auxiliary drugs) were approved for marketing in the United States, including 106 chemical drugs and 35 biological products (including 2 ADCs) Among 106 chemical drugs, 50 conventional chemotherapy drugs and 56 molecular targeted drugs were included In addition, in terms of sales, targeted small molecule drugs also maintain the leading position Lenalidomide, the top small molecule drug, mainly treats multiple myeloma, myelodysplastic syndrome and lymphoma, with sales of US $8.187 billion in 2017; rituximab, bevacizumab and trastuzumab, the three swordsmen of Roche, accounted for 2-4 of the list, with sales of US $75.67, US $72.11 and US $6.85 billion respectively Data shows that in 2017, the top 10 anti-tumor drugs in the world were all targeted anti-cancer drugs, with a total sales volume of 54.1 billion US dollars, an increase of 33.4% over the previous year, accounting for 47.9% of the global anti-tumor market share in 2017 At present, there are more than 2000 cancer treatment drugs and vaccines in different research and development stages, more than 90% of which are targeted drugs In fact, one of the major characteristics of targeted drugs is that they work on specific targets Each patient's situation is different, and the targeted drugs that can be selected are also different To a certain extent, individualized treatment of tumors can be achieved From the perspective of drug demand trend, obvious curative effect and small side effects are the main demand direction of future product development Driven by this market demand, the research and development and clinical application of targeted anti-tumor drugs will be one of the main development directions of anti-tumor drug industry in the future In general, with the increase of the global aging population and the number of new tumor cases in the future, the prospect of anti-tumor treatment is broad As one of the hot fields, the research and development of anti-tumor drugs has high investment efficiency and wide audience, and its market will increasingly become a place of war Choosing the right target drug R & D will also become one of the key to the development of pharmaceutical enterprises